This topic contains a solution. Click here to go to the answer

Author Question: A positive outcome of the client goal, client will verbalize decrease in peripheral discomfort ... (Read 73 times)

anjilletteb

  • Hero Member
  • *****
  • Posts: 569
A positive outcome of the client goal, client will verbalize decrease in peripheral discomfort (intermittent claudication) would be that the client:
 
  a. verbalizes his medication regime related to use of peripheral vasodilators.
  b. does not experience injury related to side effects of peripheral vasodilators.
  c. verbalizes that he is able to walk around the block without leg pain.
  d. reports episodes of anginal pain to the health care provider.

Question 2

The nurse should teach a client with peripheral vascular disease on vasodilator therapy about the effects of smoking, including:
 
  a. tars in tobacco increase the effectiveness of vasodilator therapy.
  b. nicotine may result in hypertension in persons taking vasodilators.
  c. nicotine has vasodilating effects that increase the effects of vasodilator therapy.
  d. the use of tobacco products should be avoided because of its vasoconstricting effects.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

aliotak

  • Sr. Member
  • ****
  • Posts: 326
Answer to Question 1

ANS: C

Feedback
A Incorrect: This addresses Deficient knowledge.
B Incorrect: This addresses Risk for injury.
C Correct: This is the positive outcome for this client's goal.
D Incorrect: This addresses Deficient knowledge.

Answer to Question 2

ANS: D

Feedback
A Incorrect: Tars decrease the effectiveness of vasodilator therapy.
B Incorrect: Nicotene can result in profound hypotension in clients taking vasodilators.
C Incorrect: Nicotene is a vasoconstrictor that decreases the effects of vasodilators.
D Correct: This is a true statement and should be included in client teaching.




aliotak

  • Sr. Member
  • ****
  • Posts: 326

 

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

More than 2,500 barbiturates have been synthesized. At the height of their popularity, about 50 were marketed for human use.

Did you know?

Autoimmune diseases occur when the immune system destroys its own healthy tissues. When this occurs, white blood cells cannot distinguish between pathogens and normal cells.

Did you know?

Earwax has antimicrobial properties that reduce the viability of bacteria and fungus in the human ear.

Did you know?

On average, the stomach produces 2 L of hydrochloric acid per day.

For a complete list of videos, visit our video library